John Swisher is a Respiratory physician affiliated with Fort Sanders Regional Medical Center. OpenAlex indexes 22 publications with 354 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6473 Kingston Pike
Knoxville, TN 37919
Telephone
865-588-8831Provider last certified this registry record 19 Feb 2025.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- United Therapeutics CorporationProgram year202539 payments$27,022openpaymentsdata.cms.gov ↗
- Actelion Pharmaceuticals US, Inc.Program year202524 payments$26,252openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
34.6%Endothelin Receptor Antagonist13.1%Opsumit55%Ambrisentan46%Part D≥23 patientsSoluble Guanylate Cyclase Stimulator10%Adempas100%Part D≥30 patients+ 5 more classes in this area
Respiratory
20.5%Corticosteroid11.6%Trelegy Ellipta83%Symbicort7%Breo Ellipta6%Fluticasone Propionate5%Part D<11 patientsbeta2-Adrenergic Agonist5.4%Albuterol Sulfate Hfa100%Part D≥51 patients+ 4 more classes in this area
Blood & clotting
19.9%Prostacycline Vasodilator13.3%Tyvaso Dpi52%Orenitram Er48%Part D<11 patientsFactor Xa inhibitor3.6%Eliquis84%Xarelto16%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Therapeutic Advances in Respiratory Disease
2025 - The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges
Vascular Health and Risk Management
2023 - Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry
Pulmonary Pharmacology & Therapeutics
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”